PMID: 9179238May 1, 1997Paper

Two ways to establish potential At-211 radiopharmaceuticals

Anticancer Research
G WunderlichS Fischer

Abstract

The special radiophysical characteristics of the alpha emitting cyclotron radionuclide At-211 favour its therapeutic application. Studies for therapeutic use have been carried out over the past 15 years. Labelling reactions with this heavy halogen and characterization of the products are important because of the low concentrations used in treatment (non carrier added level). One successful way to produce At-211 radiopharmaceuticals is the labelling of aromatic iodine compounds with At-211 via isotope exchange or reaction of organostannyl precursors with astatine. These products enter the tumour by its metabolism. To a certain extent, the intraarterial application of At-211 labelled particles seems to be a promising alternative to intravenous application, causing selective accumulation of therapeutic At-211 doses as shown by the first alpha endoradiotherapy of a incurable recurrent lingual carcinoma.

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Related Papers

International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology
T C Richardson
The Journal of Nuclear Biology and Medicine : Official Publication of the Italian Association of Nuclear Medicine (AIMN)
G WunderlichR Brossmer
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
R H LarsenMichael R Zalutsky
© 2021 Meta ULC. All rights reserved